BLA 761041, held by Genentech Inc. Atezolizumab.
As of Nov 13, 2026, BLA 761041 (Tecentriq), held by Genentech Inc, was first approved by FDA on Oct 18, 2016, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Oct 18, 2016 | Original applicationNew indication · Priority review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tecentriq1200MG/20ML · injectable; injection | Atezolizumab | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed weekly; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
